Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126581 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
NCT00126581: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00126581 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 188 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126581, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving erlotinib hydrochloride together with carboplatin and paclitaxel may kill more tumor cells than giving either drug alone.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Erlotinib
- DRUG Erlotinib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2005-08-15 |
| Est. Completion | 2017-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126581
The ClinicalTrials.gov registry entry for NCT00126581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00126581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126581 about?
NCT00126581 is a clinical study titled "Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer". This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growt...
What is the current status of trial NCT00126581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2005-08-15. Estimated completion is 2017-11-28.
What interventions are being tested in trial NCT00126581?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Erlotinib (DRUG), Erlotinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00126581?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.